COVID-19 and Its Impact on Patient Care in IBD: What Clinicians Need to Know

CMEO Webcast

Live Webcast: Tuesday, December 8, 2020
6:30 PM - 8:00 PM ET

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Wednesday, December 8, 2021

Register for Activity

Faculty


Miguel Regueiro, MD, AGAF, FACG, FACP Miguel Regueiro, MD, AGAF, FACG, FACP 
Professor and Chair
Department of Gastroenterology, Hepatology & Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Cleveland Clinic
Cleveland, OH

Florian Rieder, MD Florian Rieder, MD 
Co-Director, Inflammatory Bowel Diseases (IBD) Section
Director, IBD Research
Director, IBD Advanced Fellowship
Department of Gastroenterology, Hepatology & Nutrition
Digestive Diseases and Surgery Institute
Department of Inflammation and Immunity; Lerner Research Institute
Cleveland Clinic Foundation
Cleveland, OH

David T. Rubin, MD, FACG, AGAF, FACP, FASGE David T. Rubin, MD, FACG, AGAF, FACP, FASGE 
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Statement of Need

Coronavirus disease 2019 (COVID-19) is an unseen beast, currently ravaging the entire world, leaving no community or region untouched. In the face of this challenge, education is among the best tools that can be used to defeat it. Because inflammatory bowel disease (IBD) affects the immune system, clinicians are interested in hearing expert opinion on the best strategies for management of stable and relapsing patients with IBD during the COVID-19 pandemic.

This Live and OnDemand webcast provides clinicians with the latest information and consensus recommendations for the management of patients with IBD during the COVID-19 era. Expert faculty will also examine the latest evidence on treatment and prevention strategies for COVID-19.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Examine the latest evidence on current and emerging treatment and prevention strategies for COVID-19 and its associated symptoms in GI patients.
  • Apply optimal strategies to manage patients with IBD during the COVID-19 pandemic.
  • Identify tips and tools for providers and patients in community settings during the COVID-19 era.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Apply optimal strategies to manage patients with IBD during the COVID-19 pandemic.
  • Examine the latest evidence on current and emerging treatment and prevention strategies for COVID-19 and its associated symptoms in GI patients.
  • Identify tips and tools for providers and patients in community settings during the COVID-19 era.

Financial Support

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Gastroenterologists, nurse practitioners, nurses, PAs, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-20-151-L01-P
Enduring: 0376-0000-20-151-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory boards and a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Dr. Rieder reports that he receives grants and/or research support from Boehringer Ingelheim; Bristol-Myers Squibb Company; Morphic Therapeutic; Pfizer Inc.; Pliant Therapeutics, Inc.; and UCB, Inc. He is a consultant for AbbVie Inc.; AgomAb Therapeutics; Allergan; Boehringer-Ingelheim; Celgene Corporation/Bristol-Myers Squibb Company; CDISC; Cowen Inc.; Falk Pharma; Genentech, Inc.; Gilead Sciences, Inc.; Gossamer Bio; Guidepoint; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Koutif Therapeutics; Metacrine; Morphic Therapeutic; Origo; Prometheus Biosciences; Receptos; Redx Pharma; Samsung; Takeda Pharmaceuticals U.S.A., Inc.; Teclab, Inc.; Theravance Biopharma; Thetis Pharmaceuticals; and UCB, Inc.

Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Biomica; Boehringer Ingelheim; Bristol-Myers Squibb Company; Celgene Corporation/ Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Ichnos Sciences SA; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He is a stock shareholder (directly purchased) of AbGenomics and Biomica. He receives other financial interest or material support as Co-Founder, CFO of Cornerstones Health, Inc. (non-profit); and Co-Founder of GoDuRn, LLC.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TV-122-120820-90